Renalytix plc

Renalytix PLC

Health Information Services • Healthcare • London, United Kingdom • RENXF (OQB)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

2 Leman Street, United Kingdom

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q3 2024 Negative
Oct 1, 2024

Renalytix plc announced a significant debt restructuring, converting approximately £2.75 million of convertible bonds into equity and extending the maturity of remaining debt to 2029. Concurrently, the company is voluntarily delisting its ADSs from Nasdaq by October 7, 2024, intending to trade on the OTCQX Marketplace to streamline operations and manage financial obligations.

Recent News

REG - Renalytix PLC - Additional Subscription for 11m Shares - TradingView — Track All Markets
TradingView — Track All Markets • Sep 24
Renalytix Plc Announces £500,000 Retail Offer to Bolster Financial Position - TipRanks
TipRanks • Sep 21
15M Diabetic Kidney Patients: Renalytix and Tempus Launch Groundbreaking AI Testing Partnership - Stock Titan
Stock Titan • Sep 15
Is Renalytix Plc (Common Stock) (2O9A) stock good for long term investing - 2025 Analyst Calls & Long-Term Growth Stock Strategies - moha.gov.vn
moha.gov.vn • Nov 29
REG - Renalytix PLC - Tempus AI Inc, collaboration agreement - TradingView — Track All Markets
TradingView — Track All Markets • Sep 14

Other Health Information Services Companies

View All →
GE HealthCare Technologies Inc. logo GE Healthcare Technologies Inc.
$37.96B market cap
VEEVA SYSTEMS INC logo Veeva Systems Inc.
$36.68B market cap
Pro Medicus Ltd./ADR logo Pro Medicus Ltd.
$16.70B market cap
Tempus AI, Inc. logo Tempus AI, Inc.
$11.15B market cap
Doximity, Inc. logo Doximity, Inc.
$8.23B market cap
HEALTHEQUITY, INC. logo Healthequity, Inc.
$8.08B market cap

Frequently Asked Questions

Has Renalytix plc had layoffs?
No layoff events have been recorded for Renalytix plc in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
What industry is Renalytix plc in?
Renalytix plc operates in the Health Information Services industry, within the Healthcare sector.
Is Renalytix plc a publicly traded company?
Yes, Renalytix plc is publicly traded under the ticker symbol RENXF on the OQB. The company has a market capitalization of approximately $0.10 billion.
Where is Renalytix plc headquartered?
Renalytix plc is headquartered in London, United Kingdom at 2 Leman Street, United Kingdom.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.